CN102639142A - 内体Toll样受体活化的抑制 - Google Patents

内体Toll样受体活化的抑制 Download PDF

Info

Publication number
CN102639142A
CN102639142A CN2010800511149A CN201080051114A CN102639142A CN 102639142 A CN102639142 A CN 102639142A CN 2010800511149 A CN2010800511149 A CN 2010800511149A CN 201080051114 A CN201080051114 A CN 201080051114A CN 102639142 A CN102639142 A CN 102639142A
Authority
CN
China
Prior art keywords
nucleic acid
prr
poly
cdp
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800511149A
Other languages
English (en)
Chinese (zh)
Inventor
布鲁斯·A·萨兰格
李在元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of CN102639142A publication Critical patent/CN102639142A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2010800511149A 2009-09-16 2010-09-16 内体Toll样受体活化的抑制 Pending CN102639142A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24309009P 2009-09-16 2009-09-16
US61/243,090 2009-09-16
PCT/US2010/002516 WO2011034583A2 (en) 2009-09-16 2010-09-16 Inhibition of endosomal toll-like receptor activation

Publications (1)

Publication Number Publication Date
CN102639142A true CN102639142A (zh) 2012-08-15

Family

ID=43759220

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800511149A Pending CN102639142A (zh) 2009-09-16 2010-09-16 内体Toll样受体活化的抑制

Country Status (6)

Country Link
US (3) US9468650B2 (enExample)
EP (1) EP2477641B1 (enExample)
CN (1) CN102639142A (enExample)
CA (1) CA2774460C (enExample)
IN (1) IN2012DN02345A (enExample)
WO (1) WO2011034583A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021016924A1 (zh) * 2019-07-31 2021-02-04 中山大学 可用于治疗银屑病的阳离子聚合物及颗粒

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121354A1 (en) 2007-03-30 2008-10-09 Duke University A method of modulating the activity of a nucleic acid molecule
EP2477641B1 (en) 2009-09-16 2024-03-27 Duke University Inhibition of endosomal toll-like receptor activation for treating thrombotic disorders
US9687529B2 (en) 2011-05-05 2017-06-27 Duke University Method of controlling coagulation
WO2014169043A1 (en) * 2013-04-09 2014-10-16 Duke University Anti-inflammatory agents and methods of using the same
US10066323B2 (en) 2014-04-16 2018-09-04 Duke University Electrospun cationic nanofibers and methods of making and using the same
CN109982707A (zh) 2016-09-16 2019-07-05 杜克大学 血管性血友病因子（vwf）靶向剂及其使用方法
US12447464B2 (en) 2016-12-22 2025-10-21 Duke University Polycationic microfibers and methods of using the same
EP3601592A4 (en) 2017-03-23 2020-11-25 Duke University ANTIDOTE MEDIA INVERSION OF EXTRACELLULAR APTAMER COLOR
US20200171167A1 (en) * 2017-05-30 2020-06-04 The Trustees Of Columbia University In The City Of New York Cationic nucleic acid scavenger and uses thereof
US11713464B2 (en) 2017-09-08 2023-08-01 Duke University Nucleolin-targeting aptamers and methods of using the same
EP4249913A1 (en) * 2022-03-22 2023-09-27 Centre Hospitalier Universitaire de Nîmes Toll-like-receptor 3 inhibitor for preventing and/or treating disorders in patients with a personal history of venous thromboembolism (vte)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008000517A2 (en) * 2006-06-30 2008-01-03 Andre Koltermann Conjugates for innate immunotherapy of cancer
US20080199485A1 (en) * 2007-02-15 2008-08-21 Mannkind Corporation Method for enhancing T cell response
US20090082250A1 (en) * 2001-10-11 2009-03-26 Imperial Collegeinnovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
US20090208501A1 (en) * 2004-08-04 2009-08-20 Alberto Visintin Anti-Pathogen Immunoadhesins

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919761A (en) 1992-08-14 1999-07-06 The Board Of Regents Of The University Of Michigan Peptides for heparin and low molecular weight heparin anticoagulation reversal
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US20020037834A1 (en) 2000-09-08 2002-03-28 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
WO2002053185A2 (en) 2001-01-05 2002-07-11 Intercell Ag Anti-inflammatory use of polycationic compounds
WO2002069997A1 (en) 2001-03-08 2002-09-12 Merck Patent Gmbh Modified protamine with reduced immunogenicity
JP4773684B2 (ja) 2001-05-25 2011-09-14 デューク ユニバーシティ 薬物のモジュレータ
AUPR604101A0 (en) 2001-06-29 2001-07-26 Unisearch Limited Aptamers
WO2004033620A2 (en) 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
US20030180250A1 (en) 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
KR20050051686A (ko) 2002-10-09 2005-06-01 인설트 테라페틱스, 인코퍼레이티드 사이클로덱스트린-기초한 재료, 조성물 및 이의 용도
US20050256071A1 (en) 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
JP2006528492A (ja) 2003-07-15 2006-12-21 カリフォルニア インスティテュート オブ テクノロジー 改良されたインヒビター核酸
AU2005238490B2 (en) 2004-04-22 2010-11-18 Tobira Therapeutics, Inc. Improved modulators of coagulation factors
GB0422877D0 (en) * 2004-10-14 2004-11-17 Univ Glasgow Bioactive polymers
JP2008537551A (ja) 2005-03-31 2008-09-18 カランド ファーマシューティカルズ， インコーポレイテッド リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用
US7611835B2 (en) 2005-09-30 2009-11-03 Battelle Memorial Institute Process for preparing multilayer enzyme coating on a fiber
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
JP2009538325A (ja) 2006-05-26 2009-11-05 リガド・バイオサイエンシーズ・インコーポレーテツド Ｒｅｇ１抗凝固系の投与
WO2008066621A2 (en) 2006-10-19 2008-06-05 Duke University Reversible platelet inhibition
WO2008063157A2 (en) 2006-10-25 2008-05-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A nanoparticle-based anticoagulant
WO2008121354A1 (en) 2007-03-30 2008-10-09 Duke University A method of modulating the activity of a nucleic acid molecule
BRPI0722105A2 (pt) 2007-09-27 2014-04-08 Sca Hygiene Prod Ab Géis de polímero ligados por argila
WO2009064767A2 (en) 2007-11-12 2009-05-22 Massachusetts Institute Of Technology Bactericidal nanofibers, and methods of use thereof
WO2010020008A1 (en) 2008-08-22 2010-02-25 Polymers Crc Limited Polymer coatings
WO2010132879A2 (en) 2009-05-15 2010-11-18 The Johns Hopkins University Multicomponent degradable cationic polymers
EP2477641B1 (en) 2009-09-16 2024-03-27 Duke University Inhibition of endosomal toll-like receptor activation for treating thrombotic disorders
US20130266664A1 (en) 2010-12-20 2013-10-10 Virginia Commonwealth University Facile method for crosslinking and incorporating bioactive molecules into electrospun fiber scaffolds
WO2013040552A2 (en) 2011-09-16 2013-03-21 Georgia Health Sciences University Methods of promoting immune tolerance

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090082250A1 (en) * 2001-10-11 2009-03-26 Imperial Collegeinnovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
US20090208501A1 (en) * 2004-08-04 2009-08-20 Alberto Visintin Anti-Pathogen Immunoadhesins
WO2008000517A2 (en) * 2006-06-30 2008-01-03 Andre Koltermann Conjugates for innate immunotherapy of cancer
CN101528263A (zh) * 2006-06-30 2009-09-09 安德烈·科尔特曼 用于癌症的先天性免疫方法的缀合物
US20080199485A1 (en) * 2007-02-15 2008-08-21 Mannkind Corporation Method for enhancing T cell response

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021016924A1 (zh) * 2019-07-31 2021-02-04 中山大学 可用于治疗银屑病的阳离子聚合物及颗粒

Also Published As

Publication number Publication date
CA2774460C (en) 2016-08-09
EP2477641B1 (en) 2024-03-27
EP2477641A2 (en) 2012-07-25
WO2011034583A3 (en) 2011-10-06
US20230248805A1 (en) 2023-08-10
US20170095503A1 (en) 2017-04-06
WO2011034583A2 (en) 2011-03-24
US20120183564A1 (en) 2012-07-19
US11617779B2 (en) 2023-04-04
EP2477641A4 (en) 2013-08-07
CA2774460A1 (en) 2011-03-24
US9468650B2 (en) 2016-10-18
IN2012DN02345A (enExample) 2015-08-21

Similar Documents

Publication Publication Date Title
US20230248805A1 (en) Inhibition of endosomal toll-like receptor activation
E Gambuzza et al. Toll-like receptors in Alzheimer’s disease: a therapeutic perspective
Toy et al. TLR7 and RIG-I dual-adjuvant loaded nanoparticles drive broadened and synergistic responses in dendritic cells in vitro and generate unique cellular immune responses in influenza vaccination
US20160194642A1 (en) Spherical nucleic acid-based constructs as immunoregulatory agents
JP7410846B2 (ja) トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
US20110171209A1 (en) Potentiation of Autoimmune and Inflammatory Disease Treatments by Immune Regulatory Oligonucleotide (IRO) Antagonists of TLR7 and TLR9
US20100130425A1 (en) Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
CN107412260A (zh) cGAS-STING通路激活剂及其用途
CA2948373A1 (en) Antisense antibacterial compounds and methods
JP2017530948A (ja) 抗腫瘍組成物および方法
US20200171167A1 (en) Cationic nucleic acid scavenger and uses thereof
Noble et al. Potent immune stimulation from nanoparticle carriers relies on the interplay of adjuvant surface density and adjuvant mass distribution
C Junquera et al. Recent advances in the development of anti-Infective prophylactic and/or therapeutic agents based on toll-like receptor (TLRs)
WO2014169043A1 (en) Anti-inflammatory agents and methods of using the same
Senapati Combination nanoadjuvant-based vaccine against influenza virus for older adults
Einarsson New Resorption Pathways in Polycaprolactone: Degradation; roles of Mononuclear and Multinucleated Giant Cells
Shumansky Nucleic Acid Scavengers as Novel Regulators of Autoimmunity and Viral Infection
Toy et al. TLR7 and RIG-I dual-adjuvant loaded nanoparticles drive broadened and synergistic responses in dendritic cells and boost cellular immunity in influenza vaccination
Packard Studies on poly-ICLC treatment as a potent neuroprotective therapy against ischemic brain injury
Klinman et al. CXCL16 Influences the Nature and

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120815